SEC Filing Summary: Lion Biotechnologies, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by Lion Biotechnologies, Inc. on April 20, 2017. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The registrant is incorporated in Nevada with principal executive offices in San Carlos, California. Note: The request metadata references "IOVANCE BIOTHERAPEUTICS, INC.", but the filing text explicitly identifies the registrant as "Lion Biotechnologies, Inc."
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate presentation rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed within the text of this filing. The document solely references the distribution of a corporate presentation to analysts and stockholders.
Guidance, Outlook, and Risks
Item 7.01 discloses that the Company makes presentations to analysts and stockholders. A copy of the "Lion Biotechnologies, Inc., Corporate Presentation" is included as Exhibit 99.1. The filing explicitly states that the information in this item and the exhibit shall not be deemed "filed" for any purpose and shall not be incorporated by reference into other filings under the Securities Act of 1933 or the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the correct registrant name (Lion Biotechnologies, Inc.) versus the metadata reference (IOVANCE BIOTHERAPEUTICS, INC.).
- Review Exhibit 99.1 (Corporate Presentation) for specific business updates, as the 8-K text itself contains no operational data.
- Confirm that the presentation materials are not considered "filed" information for legal incorporation purposes.
- Check subsequent filings for financial data, as this 8-K does not contain quantitative metrics.